LANTERN PHARMA INC (LTRN) Stock Price, Forecast & Analysis
USA - NASDAQ:LTRN - US51654W1018 - Common Stock
LTRN Key Statistics, Chart & Performance
The current stock price of LTRN is 3.22 USD. In the past month the price decreased by -27.27%. In the past year, price decreased by -12.5%.
LTRN Latest News, Press Relases and Analysis
LTRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.24 | 387.94B | ||
| AMGN | AMGEN INC | 14.59 | 171.74B | ||
| GILD | GILEAD SCIENCES INC | 14.68 | 149.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.51 | 104.63B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 68.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 845.81 | 56.54B | ||
| INSM | INSMED INC | N/A | 38.71B | ||
| NTRA | NATERA INC | N/A | 26.92B | ||
| BIIB | BIOGEN INC | 9.19 | 22.55B | ||
| INCY | INCYTE CORP | 16.3 | 20.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.95 | 20.24B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.02 | 14.93B |
Related stock screener links
About LTRN
Company Profile
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Company Info
LANTERN PHARMA INC
1920 Mckinney Avenue, 7th Floor
Dallas TEXAS 75201 US
CEO: Panna Sharma
Employees: 24
Phone: 19722771136
LANTERN PHARMA INC / LTRN FAQ
Can you describe the business of LANTERN PHARMA INC?
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Can you provide the latest stock price for LANTERN PHARMA INC?
The current stock price of LTRN is 3.22 USD. The price decreased by -4.17% in the last trading session.
Does LANTERN PHARMA INC pay dividends?
LTRN does not pay a dividend.
How is the ChartMill rating for LANTERN PHARMA INC?
LTRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of LANTERN PHARMA INC (LTRN) based on its PE ratio?
LANTERN PHARMA INC (LTRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
LTRN Technical Analysis
LTRN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LTRN. LTRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LTRN Financial Highlights
Over the last trailing twelve months LTRN reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -7.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.5% | ||
| ROE | -153.71% | ||
| Debt/Equity | 0 |
LTRN Forecast & Estimates
7 analysts have analysed LTRN and the average price target is 20.4 USD. This implies a price increase of 533.54% is expected in the next year compared to the current price of 3.22.